
Prominex, Inc.: A leading US biotech firm specializing in point-of-care molecular diagnostic assays.
Prominex, Inc., founded with a mission to revolutionize point-of-care infectious disease testing, is a leading biotechnology company based in the United States. The company's core vision is to provide rapid, accurate, and affordable molecular diagnostic assays that can deliver test results in minutes. Prominex's product offerings are designed to be easy-to-use, reusable, and scalable, making them accessible for a wide range of healthcare settings. Their primary market focus is on developing advanced diagnostic solutions for infectious diseases.
Notable achievements for Prominex include receiving funding from the NIH RADx® Tech program to advance their sample-to-answer molecular assay system. This recognition underscores their commitment to high-performance and accessible diagnostic testing. The company's innovative approach has positioned it as a significant player in the biotech industry, contributing to improved healthcare outcomes through faster and more reliable diagnostics.

Prompt Diagnostics
prompt-dx.com

Proxim Diagnostics
proximdx.com

Anavasi Diagnostics
anavasidx.com

Test Diagnostics

AmplifiDx
amplifidx.com

NAT Diagnostics

Novel Microdevices
noveldx.com

Genendeavor
genendeavor.com

Exactus

SenGenix
sengenix.com

DxNA

Molecular Detection

OmniVis

Minute Molecular Diagnostics

Torus Biosystems
Companies similar to Prominex include Prompt Diagnostics, Proxim Diagnostics, Anavasi Diagnostics and Test Diagnostics.
Prominex was founded in 2016.
Prominex's headquarters is located in San Diego, CA, US.
Prominex's most recent funding round was for $4M (USD) in September 2018.
As of Sep 13, 2018, Prominex has raised a total of $4M (USD).
Prominex has 13 employees as of Feb 4, 2024.